New pharmacologic agents for diabetes.

被引：8

作者：

Bailey C.J. ^{[1
]}

机构：

[1] Department of Pharmaceutical Sciences, Aston University, Aston Triangle

来源：

Current Diabetes Reports | 2001年 / 1卷 / 2期

关键词：

Troglitazone; Lipoic Acid; Sibutramine; Hepatic Glucose Output; Improve Insulin Action;

D O I：

10.1007/s11892-001-0023-9

中图分类号：

学科分类号：

摘要：

New agents are being developed to address the underlying endocrinopathies and metabolic disturbances of type 2 diabetes. Stimulants of the nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) are being identified to selectively improve insulin actions, and dual agonists of PPAR gamma and PPAR alpha are being evaluated for enhanced control of hyperglycemia and dyslipidemia. Novel activators of insulin receptor phosphorylation and inhibitors of receptor dephosphorylation are offering encouraging leads for new agents. Analogues of glucagon-like peptide-1 that increase glucose-induced insulin secretion may additionally increase beta-cell neogenesis from progenitor duct cells. The amylin analogue pramlintide, which suppresses glucagon secretion and reduces weight, is advancing in clinical trial. Direct stimulants of glucose utilization and partial inhibitors of gluconeogenesis are providing useful new drug templates. Thus, new pharmacologic approaches are emerging to treat the multiple lesions of type 2 diabetes.

引用

页码：119 / 126

页数：7

共 202 条

[21]

Sreenan S(1992)NIP-221 is a novel and potent thiazolidinedione-based peroxisome proliferator activated receptor (PPAR) γ ligand with a prolonged biological half-time J Med Chem 35 2617-2626

[22]

Hirano K(2000)Studies on antidiabetic agents. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents Diabetes Obesity Metab 2 155-163

[23]

Furnsinn C(2000)Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione Diabetes 49 A157-A157

[24]

Brunmair B(2000)Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, improves metabolic control in type 2 diabetes mellitus patients Diabetes 48 1415-1424

[25]

Meyer M(2001)A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-g reverses the diabetic phenotype of the Zucker diabetic fatty rat Endocrinology 142 1269-1277

[26]

Loviscach M(1999)Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues J Biol Chem 274 7913-7922

[27]

Rehman N(1996)L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding Endocrinology 137 4189-4195

[28]

Carter L(1998)Thiazolidinediones produce a conformational change in peroxisome proliferator- activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice Nature 395 137-143

[29]

Cha BS(2000) receptor-g Diabetes 49 539-547

[30]

Ciaraldi TP(2000)Differential activation of peroxisome proliferator-activated receptor-g by troglitazone Diabetologia 43 1165-1169

← 1 2 3 4 5 6 7 8 9 10 →